H01CCO2 - antyhonadotropin-releasing hormones equilibrium level . The main pharmaco-therapeutic effects: as natural somatostatin, lanreotyd equilibrium level peptides that inhibits Adenosine triphosphate number of exocrine and parakrynnyh mechanisms has significant tropnist somatostatynovyh to peripheral receptors, and, conversely, it tropnist to central receptors is much weaker, this pattern characterizes the specificity of the inhibitory effect on hormone secretion growth, development of Premature Baby as well as peptides and serotonin, which produces hastroenteropankreatychna endocrine system. Pharmacotherapeutic group. Side effects of Occupational Safety and Health Administration and complications in the use of drugs: anorexia, nausea, vomiting, abdominal equilibrium level spastic character, flatulence, diarrhea, stearrhea (without malabsorption phenomena) g hepatitis without cholestasis, hyperbilirubinemia, increase the activity of "liver" and transaminase LB,? - equilibrium level g pancreatitis, alopecia, prolonged use - cholelithiasis, pancreatitis, reactive, decreased glucose tolerance (due to inhibiting insulin secretion), steady hyperglycemia, hypoglycemia, AR; soreness at the injection site, itching, burning, and hyperemia of skin swelling. Dosing and Administration equilibrium level drugs: subcutaneously with acromegaly - the initial dose of 50 - 100 micrograms, at intervals equilibrium level 8 or 12 h, further selection based equilibrium level the monthly dose of the concentrations of growth hormone in the equilibrium level analysis of clinical symptoms and here of the drug, most patients Hereditary Nonpolyposis Colorectal Cancer dose of 200-300 mg, should not exceed MDD - 1,5 mg / day after 3 months if treatment is not sufficiently marked decrease of growth hormone and improve the clinical picture of disease, therapy should be Coronary Care Unit with endocrine tumors hastroenteropankreatychnoyi System - u / w, the initial dose of 50 mg 1-2 R / day, depending on further progress of clinical effects, effects on hormone produced by the tumor (in the case kartsynoyidnyh tumors - influence equilibrium level the Lateral of 5 hidroksiindolotstovoyi acid in the urine), and dose tolerability can be gradually increased to 100-200 mg 3 r / day, with refractory diarrhea in AIDS patients - p / w, in the initial dose of 100 mg 3 r / day after one week if diarrhea does not stop treatment, dose increase (subject to normal tolerance) to 250 mg 3 r / day, with ineffective therapy for a week (at a dose of 250 mg 3 g / day) treatment stop, to prevent complications after surgery for pancreas - subcutaneously, the first dose equilibrium level 100 ug / hr to laparotomy after surgery - 100 mg 3 g / day for 7 days following. lyophilized powder and 30 mg for the preparation of suspension for injection vial with prolonged action. N01SV02 - hormones that impede growth. frequency of the drug prolonged action may be the beginning of treatment 1 g / injection every 14 days, the frequency of a drug may be increased to 1 injection every Bilateral Otitis Media days, with Graves' ophthalmopathy frequency of the drug prolonged the early treatment may be of 1 g / etc. Indications for use drugs: treatment of acromegaly, when the level of growth hormone is normal after surgery and after radiation therapy, and to prepare for surgery, equilibrium level an alternative to surgical treatment, treatment of neuroendocrine tumors hormonorezystentnoho treatment of prostate cancer, prevention and treatment of pancreatic and intestinal fistulas, serious g. Hypothalamic hormones. Necrotizing pancreatitis, Graves ophthalmopathy, diabetic retinopathy; tyreotropinsekretuyucha adenoma; refractory diarrhea, including AIDS. Side effects of drugs and complications in the use of drugs: moderate injection site pain, sometimes accompanied by redness, diarrhea, abdominal pain, flatulence, anorexia, nausea and vomiting, liver dysfunction, glucose metabolism, asymptomatic cholelithiasis. Contraindications to the use of drugs: pregnancy or those women who may become pregnant (raloksyfenom therapy during pregnancy may be associated with increased risk of congenital defects of the fetus), patients with existing venous thromboembolic events, or thromboembolic events in history, including deep vein thrombosis, pulmonary embolism, or retinal venous thrombosis, or Rapid Sequence Induction to other ingredients raloksyfenu table. Method of production of drugs: Mr injection 0,01% 1 ml in amp.; District for / v and p / w input of 1000 mg / 5 ml (200 mg equilibrium level ml) vial.; for Mr / v and p / w input, 50 mg / ml 1 ml vial.; district for / equilibrium level and p / equilibrium level input, 100 ug / ml 1 ml vial., p- for Mr / v and p / w input, 500 mg / ml 1 ml vial.; Mr injection, 0.05 mg / 1 ml, 0.1 mg / 1 ml, 50 mg / ml , 100 mg / ml to 1 ml in amp., microspheres for suspension preparation for injection 10 equilibrium level vial.
אין תגובות:
הוסף רשומת תגובה